Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea

Boyoung Park, Sohee Park, Hai Rim Shin, Aesun Shin, Yohwan Yeo, Ji Yeob Choi, Kyu Won Jung, Byoung Gie Kim, Yong Man Kim, Dong Young Noh, Sei Hyun Ahn, Jae Weon Kim, Sokbom Kang, Jae-Hoon Kim, Tae Jin Kim, Daehee Kang, Keun Young Yoo, Sue K. Park

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Breast and ovarian cancers are predominant female cancers with increasing prevalence. The purpose of this study was to estimate the population attributable risks (PARs) of breast and ovarian cancer occurrence based on the relative risks (RRs) of modifiable reproductive factors and population-specific exposure prevalence. Methods: The PAR was calculated by using the 1990 standardized prevalence rates, the 2010 national cancer incidence with a 20 year lag period, the meta-analyzed RRs from studies conducted in the Korean population for breast cancer, and the meta-analyzed RRs from a Korean epithelial ovarian cancer study and a prior meta-analysis, and ovarian cancer cohort results up to 2012. For oral contraceptive and hormone replacement therapy use, we did not consider lag period. Results: The summary PARs for modifiable reproductive factors were 16.7 % (95 % CI 15.8-17.6) for breast cancer (2404 cases) and 81.9 % (95 % CI 55.0-100.0) for ovarian cancer (1579 cases). The modifiable reproductive factors included pregnancy/age at first birth (8.0 %), total period of breastfeeding (3.1 %), oral contraceptive use (5.3 %), and hormone replacement therapy use (0.3 %) for breast cancer and included breastfeeding experience (2.9 %), pregnancy (1.2 %), tubal ligation (24.5 %), and oral contraceptive use (53.3 %) for ovarian cancer. Conclusions: Despite inherent uncertainties in the risk factors for breast and ovarian cancers, we suggest that appropriate long-term control of modifiable reproductive factors could reduce breast and ovarian cancer incidences and their related burdens by 16.7 % and 81.9 %, respectively.

Original languageEnglish
Article number5
JournalBMC cancer
Volume16
Issue number1
DOIs
Publication statusPublished - 2016 Jan 6

Fingerprint

Korea
Ovarian Neoplasms
Breast Neoplasms
Population
Oral Contraceptives
Hormone Replacement Therapy
Breast Feeding
Tubal Sterilization
Pregnancy
Birth Order
Incidence
Uncertainty
Meta-Analysis
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Park, B., Park, S., Shin, H. R., Shin, A., Yeo, Y., Choi, J. Y., ... Park, S. K. (2016). Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea. BMC cancer, 16(1), [5]. https://doi.org/10.1186/s12885-015-2040-0
Park, Boyoung ; Park, Sohee ; Shin, Hai Rim ; Shin, Aesun ; Yeo, Yohwan ; Choi, Ji Yeob ; Jung, Kyu Won ; Kim, Byoung Gie ; Kim, Yong Man ; Noh, Dong Young ; Ahn, Sei Hyun ; Kim, Jae Weon ; Kang, Sokbom ; Kim, Jae-Hoon ; Kim, Tae Jin ; Kang, Daehee ; Yoo, Keun Young ; Park, Sue K. / Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea. In: BMC cancer. 2016 ; Vol. 16, No. 1.
@article{d629c4b2a73943cbaf8e9b080ff650b6,
title = "Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea",
abstract = "Background: Breast and ovarian cancers are predominant female cancers with increasing prevalence. The purpose of this study was to estimate the population attributable risks (PARs) of breast and ovarian cancer occurrence based on the relative risks (RRs) of modifiable reproductive factors and population-specific exposure prevalence. Methods: The PAR was calculated by using the 1990 standardized prevalence rates, the 2010 national cancer incidence with a 20 year lag period, the meta-analyzed RRs from studies conducted in the Korean population for breast cancer, and the meta-analyzed RRs from a Korean epithelial ovarian cancer study and a prior meta-analysis, and ovarian cancer cohort results up to 2012. For oral contraceptive and hormone replacement therapy use, we did not consider lag period. Results: The summary PARs for modifiable reproductive factors were 16.7 {\%} (95 {\%} CI 15.8-17.6) for breast cancer (2404 cases) and 81.9 {\%} (95 {\%} CI 55.0-100.0) for ovarian cancer (1579 cases). The modifiable reproductive factors included pregnancy/age at first birth (8.0 {\%}), total period of breastfeeding (3.1 {\%}), oral contraceptive use (5.3 {\%}), and hormone replacement therapy use (0.3 {\%}) for breast cancer and included breastfeeding experience (2.9 {\%}), pregnancy (1.2 {\%}), tubal ligation (24.5 {\%}), and oral contraceptive use (53.3 {\%}) for ovarian cancer. Conclusions: Despite inherent uncertainties in the risk factors for breast and ovarian cancers, we suggest that appropriate long-term control of modifiable reproductive factors could reduce breast and ovarian cancer incidences and their related burdens by 16.7 {\%} and 81.9 {\%}, respectively.",
author = "Boyoung Park and Sohee Park and Shin, {Hai Rim} and Aesun Shin and Yohwan Yeo and Choi, {Ji Yeob} and Jung, {Kyu Won} and Kim, {Byoung Gie} and Kim, {Yong Man} and Noh, {Dong Young} and Ahn, {Sei Hyun} and Kim, {Jae Weon} and Sokbom Kang and Jae-Hoon Kim and Kim, {Tae Jin} and Daehee Kang and Yoo, {Keun Young} and Park, {Sue K.}",
year = "2016",
month = "1",
day = "6",
doi = "10.1186/s12885-015-2040-0",
language = "English",
volume = "16",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

Park, B, Park, S, Shin, HR, Shin, A, Yeo, Y, Choi, JY, Jung, KW, Kim, BG, Kim, YM, Noh, DY, Ahn, SH, Kim, JW, Kang, S, Kim, J-H, Kim, TJ, Kang, D, Yoo, KY & Park, SK 2016, 'Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea', BMC cancer, vol. 16, no. 1, 5. https://doi.org/10.1186/s12885-015-2040-0

Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea. / Park, Boyoung; Park, Sohee; Shin, Hai Rim; Shin, Aesun; Yeo, Yohwan; Choi, Ji Yeob; Jung, Kyu Won; Kim, Byoung Gie; Kim, Yong Man; Noh, Dong Young; Ahn, Sei Hyun; Kim, Jae Weon; Kang, Sokbom; Kim, Jae-Hoon; Kim, Tae Jin; Kang, Daehee; Yoo, Keun Young; Park, Sue K.

In: BMC cancer, Vol. 16, No. 1, 5, 06.01.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea

AU - Park, Boyoung

AU - Park, Sohee

AU - Shin, Hai Rim

AU - Shin, Aesun

AU - Yeo, Yohwan

AU - Choi, Ji Yeob

AU - Jung, Kyu Won

AU - Kim, Byoung Gie

AU - Kim, Yong Man

AU - Noh, Dong Young

AU - Ahn, Sei Hyun

AU - Kim, Jae Weon

AU - Kang, Sokbom

AU - Kim, Jae-Hoon

AU - Kim, Tae Jin

AU - Kang, Daehee

AU - Yoo, Keun Young

AU - Park, Sue K.

PY - 2016/1/6

Y1 - 2016/1/6

N2 - Background: Breast and ovarian cancers are predominant female cancers with increasing prevalence. The purpose of this study was to estimate the population attributable risks (PARs) of breast and ovarian cancer occurrence based on the relative risks (RRs) of modifiable reproductive factors and population-specific exposure prevalence. Methods: The PAR was calculated by using the 1990 standardized prevalence rates, the 2010 national cancer incidence with a 20 year lag period, the meta-analyzed RRs from studies conducted in the Korean population for breast cancer, and the meta-analyzed RRs from a Korean epithelial ovarian cancer study and a prior meta-analysis, and ovarian cancer cohort results up to 2012. For oral contraceptive and hormone replacement therapy use, we did not consider lag period. Results: The summary PARs for modifiable reproductive factors were 16.7 % (95 % CI 15.8-17.6) for breast cancer (2404 cases) and 81.9 % (95 % CI 55.0-100.0) for ovarian cancer (1579 cases). The modifiable reproductive factors included pregnancy/age at first birth (8.0 %), total period of breastfeeding (3.1 %), oral contraceptive use (5.3 %), and hormone replacement therapy use (0.3 %) for breast cancer and included breastfeeding experience (2.9 %), pregnancy (1.2 %), tubal ligation (24.5 %), and oral contraceptive use (53.3 %) for ovarian cancer. Conclusions: Despite inherent uncertainties in the risk factors for breast and ovarian cancers, we suggest that appropriate long-term control of modifiable reproductive factors could reduce breast and ovarian cancer incidences and their related burdens by 16.7 % and 81.9 %, respectively.

AB - Background: Breast and ovarian cancers are predominant female cancers with increasing prevalence. The purpose of this study was to estimate the population attributable risks (PARs) of breast and ovarian cancer occurrence based on the relative risks (RRs) of modifiable reproductive factors and population-specific exposure prevalence. Methods: The PAR was calculated by using the 1990 standardized prevalence rates, the 2010 national cancer incidence with a 20 year lag period, the meta-analyzed RRs from studies conducted in the Korean population for breast cancer, and the meta-analyzed RRs from a Korean epithelial ovarian cancer study and a prior meta-analysis, and ovarian cancer cohort results up to 2012. For oral contraceptive and hormone replacement therapy use, we did not consider lag period. Results: The summary PARs for modifiable reproductive factors were 16.7 % (95 % CI 15.8-17.6) for breast cancer (2404 cases) and 81.9 % (95 % CI 55.0-100.0) for ovarian cancer (1579 cases). The modifiable reproductive factors included pregnancy/age at first birth (8.0 %), total period of breastfeeding (3.1 %), oral contraceptive use (5.3 %), and hormone replacement therapy use (0.3 %) for breast cancer and included breastfeeding experience (2.9 %), pregnancy (1.2 %), tubal ligation (24.5 %), and oral contraceptive use (53.3 %) for ovarian cancer. Conclusions: Despite inherent uncertainties in the risk factors for breast and ovarian cancers, we suggest that appropriate long-term control of modifiable reproductive factors could reduce breast and ovarian cancer incidences and their related burdens by 16.7 % and 81.9 %, respectively.

UR - http://www.scopus.com/inward/record.url?scp=84955758466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955758466&partnerID=8YFLogxK

U2 - 10.1186/s12885-015-2040-0

DO - 10.1186/s12885-015-2040-0

M3 - Article

VL - 16

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 5

ER -